Literature DB >> 16289710

Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003).

G C Schito1, D Felmingham.   

Abstract

Isolates of Streptococcus pneumoniae collected over the first 4 years of the PROTEKT study were tested for susceptibility to penicillin, azithromycin and telithromycin. A total of 20,750 isolates were collected from 39 countries. Penicillin non-susceptibility rates were stable over the study period; overall, 21.8% of isolates were resistant. Azithromycin resistance increased from 31.0% in Year 1 to 36.3% in Year 4. Resistance rates for penicillin and azithromycin varied between countries and were highest in France, Spain, South Africa, USA and the Far East. Multidrug resistance in S. pneumoniae did not change significantly over the 4 years, with an overall rate of 38.6%. Telithromycin retained good activity against S. pneumoniae (0.1% of isolates resistant), including multidrug-resistant isolates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16289710     DOI: 10.1016/j.ijantimicag.2005.04.022

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  9 in total

Review 1.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 2.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Polyclonal population structure of Streptococcus pneumoniae isolates in Spain carrying mef and mef plus erm(B).

Authors:  Elia Gómez G de la Pedrosa; María-Isabel Morosini; Mark van der Linden; Patricia Ruiz-Garbajosa; Juan Carlos Galán; Fernando Baquero; Ralf René Reinert; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2008-03-24       Impact factor: 5.191

4.  Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.

Authors:  Xiaoping Xu; Lin Cai; Meng Xiao; Fanrong Kong; Shahin Oftadeh; Fei Zhou; Gwendolyn L Gilbert
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

5.  Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.

Authors:  Laura Calatayud; C Ardanuy; E Cercenado; A Fenoll; E Bouza; R Pallares; R Martín; J Liñares
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

6.  Antimicrobial susceptibility of Streptococcus pneumoniae in adult patients with pneumococcal pneumonia in an urban hospital in Mozambique.

Authors:  Jeannet C Bos; Sara J Beishuizen; Geoffrey C Madeira; Elmano dos Santos Gomonda; Esmeralda O Cossa; Augusto C Macome; Reindert P van Steenwijk; Constance Schultsz; Jan M Prins
Journal:  BMC Res Notes       Date:  2014-02-25

7.  The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae.

Authors:  Josef Yayan
Journal:  Drug Des Devel Ther       Date:  2014-10-03       Impact factor: 4.162

8.  Prevalence of nasopharyngeal Streptococcus pneumoniae carriage and resistance to macrolides in the setting of azithromycin mass drug administration: analysis from a cluster-randomised controlled trial in Malawi, 2015-17.

Authors:  John D Hart; Lyson Samikwa; Harry Meleke; Sarah E Burr; Jen Cornick; Khumbo Kalua; Robin L Bailey
Journal:  Lancet Microbe       Date:  2022-02

9.  A 2011-2012 survey of doctors' perceptions of korean guidelines and empirical treatment of community-acquired pneumonia.

Authors:  Hye-In Kim; Shin-Woo Kim; Hyun-Ha Chang; Jong-Myung Lee; Kyong Ran Peck
Journal:  Infect Chemother       Date:  2013-12-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.